Parenteral Cosmetic cross-reference

Magnesium Chloride Anhydrous

CAS 7786-30-3

Magnesium Chloride Anhydrous (CAS 7786-30-3) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 618 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
618
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Magnesium Chloride Anhydrous
CAS Number
7786-30-3
UNII
59XN63C8VM
InChIKey
TWRXJAOTZQYOKJ-UHFFFAOYSA-L
ChEMBL ID
CHEMBL2219642
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
parenteral
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL2219642 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Death 1122 1607.984 10011906
Peritonitis bacterial 320 1395.911 10062070
Peritonitis 290 917.396 10034674
Toxic anterior segment syndrome 177 875.868 10066366
Peritoneal dialysis complication 169 857.341 10067594
Fungal peritonitis 112 601.765 10061138
Device interaction 74 397.277 10012586
Encapsulating peritoneal sclerosis 52 255.951 10075012
Sepsis 261 238.001 10040047
Endophthalmitis 73 228.044 10014801
Ultrafiltration failure 37 201.044 10069568
Myocardial infarction 185 179.118 10028596
Cardiac disorder 126 171.053 10061024
Peritoneal cloudy effluent 29 153.939 10067011
Hypervolaemia 88 148.131 10020919
Cardiac failure 150 142.83 10007554
Post procedural complication 72 140.443 10058046
Gangrene 53 136.437 10017711
Cardiac arrest 148 135.358 10007515
Cardiovascular disorder 65 132.042 10007649
Blood glucose false positive 20 121.12 10005556
Drug ineffective 40 111.231 10013709
Anterior chamber cell 27 110.346 10053781
Noninfectious peritonitis 20 103.635 10071648
Cataract operation complication 19 93.157 10057419
Bloody peritoneal effluent 16 81.335 10067442
Catheter site infection 30 72.004 10056520
Cerebrovascular accident 105 65.773 10008190
Hypoglycaemia 79 63.711 10020993
Eye inflammation 29 62.877 10015943
Anterior chamber disorder 12 56.631 10061641
Marasmus 15 50.135 10026820
Pneumonia 235 48.872 10035664
Abdominal distension 79 48.769 10000060
Peritoneal effluent abnormal 8 46.841 10069638
Tonsillar haemorrhage 10 43.032 10057450
Procedural complication 23 42.687 10057765
Corneal oedema 16 42.087 10011033
Drug intolerance 4 40.615 10061822
Diabetic foot 17 40.447 10060734
Anterior chamber inflammation 11 39.407 10054765
Diabetic complication 13 38.18 10061104
Hernia 29 38.057 10019909
Hypotension 153 37.628 10021097
Keratitis 17 36.824 10023332
Peritoneal disorder 11 36.685 10061343
Regurgitation 15 36.404 10067171
Multimorbidity 12 35.027 10063914
Toxicity to various agents 11 34.56 10070863
Localised infection 38 34.417 10024774

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Magnesium Chloride Anhydrous used for in pharmaceutical contexts?

Magnesium Chloride Anhydrous (CAS 7786-30-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Magnesium Chloride Anhydrous?

Magnesium Chloride Anhydrous has 618 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Death, Peritonitis bacterial, Peritonitis, Toxic anterior segment syndrome, Peritoneal dialysis complication. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Magnesium Chloride Anhydrous also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Bischofite Magnesium Chloride with EU status "permitted".

What clinical phase is Magnesium Chloride Anhydrous in?

Magnesium Chloride Anhydrous is rendered with ChEMBL max phase 4 (approved).